Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Tamara Ecclestone is criticised as her daughter Fifi, 10, heads out wearing heavy make
Tamara Ecclestone has been criticised after her 10-year-old daughter Fifi headed out wearing heavy m2024-05-22Draft gov't work report discussed at key meeting
China's policymakers pledged on Thursday to further invigorate the economy, prevent and defuse risks2024-05-22China 'disappointed' as U.S. blocks Gaza ceasefire for 4th time at UN
A Chinese envoy to the United Nations on Tuesday reiterated disappointment with the United States fo2024-05-22China's national legislature to hold press conference ahead of annual session
The second session of the 14th National People's Congress will hold a press conference on March 4 at2024-05-22Climber found dead on Denali, North America's tallest peak
ANCHORAGE, Alaska (AP) — A climber was found dead on North America’s tallest peak, Denali, on Monday2024-05-22Envoy calls for upholding multilateralism
Actions: Xi's vision 'points the way forward for the world'To address global challenges, the world's2024-05-22
atest comment